Should chemotherapy plus immune checkpoint inhibition be the standard front ‐line therapy for patients with metastatic non–small cell lung cancer?
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Sarah B. Goldberg,
Roy S. Herbst Tags: Insight from the Experts Source Type: research
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin ‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
ConclusionsSingle ‐agent nab‐paclitaxel was associated with promising outcomes and a tolerable safety profile as second‐line treatment for patients with advanced‐stage, nonsquamous non‐small cell lung cancer. There was no benefit from the addition of CC‐486 to nab‐paclitaxel. (Source: Cancer)
Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Daniel Morgensztern,
Manuel Cobo,
Santiago Ponce Aix,
Pieter E. Postmus,
Conrad R. Lewanski,
Jaafar Bennouna,
J ürgen R. Fischer,
Oscar Juan‐Vidal,
David J. Stewart,
Gianpiero Fasola,
Andrea Ardizzoni,
Rafia Bhore,
Marianne Wolfsteiner,
De Tags: Original Article Source Type: research
Estimating child mortality associated with maternal mortality from breast and cervical cancer
ConclusionsTo the authors ’ knowledge, this is the first study to estimate the impact of a mother’s death from cancer on child mortality. The model’s estimates call for further investigation into this correlation and underscore the relevance of adequate access to prevention and treatment among women of childbearing age . (Source: Cancer)
Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Raymond B. Mailhot Vega,
Onyinye D. Balogun,
Omar F. Ishaq,
Freddie Bray,
Ophira Ginsburg,
Silvia C. Formenti Tags: Original Article Source Type: research
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF ‐mutated melanoma and other advanced malignancies
ConclusionsThe combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma andBRAFV600 mutations, regardless of prior treatment with BRAF and/or MEK inhibitors. (Source: Cancer)
Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Minny Bhatty,
Shumei Kato,
Sarina A. Piha ‐Paul,
Aung Naing,
Vivek Subbiah,
Helen J. Huang,
Daniel D. Karp,
Apostolia M. Tsimberidou,
Ralph G. Zinner,
Wen‐Jen Hwu,
Milind Javle,
Sapna P. Patel,
Mimi I. Hu,
Gauri R. Varadhachary,
Anthony Tags: Original Article Source Type: research
Quantitative imaging of cancer in the postgenomic era: Radio(geno)mics, deep learning, and habitats
Although cancer often is referred to as “a disease of the genes,” it is indisputable that the (epi)genetic properties of individual cancer cells are highly variable, even within the same tumor. Hence, preexisting resistant clones will emerge and proliferate after therapeutic selection that targets sensitive clones. Herein, the authors propose that quantitative image analytics, known as “radiomics,” can be used to quantify and characterize this heterogeneity. Virtually every patient with cancer is imaged radiologically. Radiomics is predicated on the beliefs that these images reflect underlying pathophysiologies, an...
Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Sandy Napel,
Wei Mu,
Bruna V. Jardim ‐Perassi,
Hugo J.W.L. Aerts,
Robert J. Gillies Tags: Review Article Source Type: research
Should chemotherapy plus immune checkpoint inhibition be the standard front ‐line therapy for patients with metastatic non–small cell lung cancer?
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Sarah B. Goldberg,
Roy S. Herbst Source Type: research
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF ‐mutated melanoma and other advanced malignancies
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Minny Bhatty,
Shumei Kato,
Sarina A. Piha ‐Paul,
Aung Naing,
Vivek Subbiah,
Helen J. Huang,
Daniel D. Karp,
Apostolia M. Tsimberidou,
Ralph G. Zinner,
Wen‐Jen Hwu,
Milind Javle,
Sapna P. Patel,
Mimi I. Hu,
Gauri R. Varadhachary,
Anthony Source Type: research
Quantitative imaging of cancer in the postgenomic era: Radio(geno)mics, deep learning, and habitats
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Sandy Napel,
Wei Mu,
Bruna V. Jardim ‐Perassi,
Hugo J.W.L. Aerts,
Robert J. Gillies Source Type: research
ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin ‐bound paclitaxel with or without CC‐486 as second‐line treatment for advanced nonsquamous non‐small cell lung cancer (NSCLC)
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Daniel Morgensztern,
Manuel Cobo,
Santiago Ponce Aix,
Pieter E. Postmus,
Conrad R. Lewanski,
Jaafar Bennouna,
J ürgen R. Fischer,
Oscar Juan‐Vidal,
David J. Stewart,
Gianpiero Fasola,
Andrea Ardizzoni,
Rafia Bhore,
Marianne Wolfsteiner,
De Source Type: research
Estimating child mortality associated with maternal mortality from breast and cervical cancer
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - November 1, 2018 Category: Cancer & Oncology Authors: Raymond B. Mailhot Vega,
Onyinye D. Balogun,
Omar F. Ishaq,
Freddie Bray,
Ophira Ginsburg,
Silvia C. Formenti Source Type: research
Changes in body mass index, height, and weight in children during and after therapy for acute lymphoblastic leukemia
ConclusionsThe results of the current study demonstrate that obesity is prevalent, and height growth, especially in patients with identified risk factors, appears compromised. Multidisciplinary intervention should begin during induction therapy and continue during the off ‐therapy period. (Source: Cancer)
Source: Cancer - October 25, 2018 Category: Cancer & Oncology Authors: Emily K. Browne,
Yinmei Zhou,
Wassim Chemaitilly,
John C. Panetta,
Kirsten K. Ness,
Sue C. Kaste,
Cheng Cheng,
Mary V. Relling,
Ching ‐Hon Pui,
Hiroto Inaba Tags: Original Article Source Type: research
Identifying optimal approaches to implement colorectal cancer screening through participation in a learning laboratory
Cancer, EarlyView. (Source: Cancer)
Source: Cancer - October 25, 2018 Category: Cancer & Oncology Authors: Florence K.L. Tangka,
Sujha Subramanian,
Amy S. DeGroff,
Faye L. Wong,
Lisa C. Richardson Tags: Foreword Source Type: research
Evaluation of patient ‐focused interventions to promote colorectal cancer screening among New York state Medicaid managed care patients
ConclusionsScreening uptake was low and did not differ significantly across the 2 regions or within the 3 cohorts. The incentive payment and mailed reminder did not appear to be effective in increasing CRC screening. The total cost of implementation was lower in the Central Region because of efficiencies generated from lessons learned during the first round of implementation in the Adirondack Region. More varied multicomponent interventions may be required to facilitate the completion of CRC screening among Medicaid beneficiaries.Cancer 2018;124:000 ‐000. (Source: Cancer)
Source: Cancer - October 25, 2018 Category: Cancer & Oncology Authors: Heather L. M. Dacus,
Victoria L. Wagner,
Elis è A. Collins,
Jacqueline M. Matson,
Margaret Gates,
Sonja Hoover,
Florence K. L. Tangka,
Teri Larkins,
Sujha Subramanian Tags: Original Article Source Type: research
Colorectal cancer screening interventions in 2 health care systems serving disadvantaged populations: Screening uptake and cost ‐effectiveness
ConclusionsIn both health systems, the multicomponent interventions implemented likely resulted in improvements in CRC screening. The results suggest that significant increases in CRC screening uptake can be achieved in federally qualified health centers when appropriate technical support and health system commitment are present. The cost estimates of the multicomponent interventions suggest that these interventions and support activities can be implemented in a cost ‐effective manner. (Source: Cancer)
Source: Cancer - October 25, 2018 Category: Cancer & Oncology Authors: Christen L. Lara,
Kelly L. Means,
Krystal D. Morwood,
Westley R. Lighthall,
Sonja Hoover,
Florence K.L. Tangka,
Cynthia French,
Krystal D. Gayle,
Amy DeGroff,
Sujha Subramanian Tags: Original Article Source Type: research
Economic assessment of patient navigation to colonoscopy ‐based colorectal cancer screening in the real‐world setting at the University of Chicago Medical Center
ConclusionsThe current findings indicate that non ‐nurse PN can increase colonoscopy completion, and this can be achieved at a minimal incremental cost for an insured population at an urban academic medical center. (Source: Cancer)
Source: Cancer - October 25, 2018 Category: Cancer & Oncology Authors: Karen E. Kim,
Fornessa Randal,
Matt Johnson,
Michael Quinn,
Chieko Maene,
Sonja Hoover,
Valerie Richmond ‐Reese,
Florence K. L. Tangka,
Djenaba A. Joseph,
Sujha Subramanian Tags: Original Article Source Type: research
